Newer Antidepressants Effective, Well-Tolerated for Parkinson’s Patients
A new study presents good news for individuals diagnosed with both Parkinson’s disease and depression.
“Depression is the number-one factor negatively affecting the quality of life for people with Parkinson’s disease,” said Irene Hegeman Richard, M.D., who led the study.
“It causes a great deal of suffering among patients. The great news here is that it’s treatable. And when the depression is treated adequately, many of the other symptoms become much more manageable for patients.”
The findings are good news for patients with Parkinson’s disease, as about half of Parkinson’s patients also struggle with depression.
“It’s very important to note that these patients are not depressed simply because they are dealing with a chronic neurological condition,” said Richard. “Rather, the depression is caused by the underlying disease process, which also causes problems with movement and balance.”
Older tricyclic depression medications reduced depression but had significant side effects. This discovery caused physician to be cautious in the use of the newer class of antidepressant called selective serotonin reuptake inhibitors (SSRIs).
That led physicians to try newer medications in Parkinson’s patients. However, some smaller studies with these medications had mixed results, leaving some physicians to question whether these drugs were actually of any benefit. In addition, there was some concern that they might worsen patient’s motor symptoms.
The new study sought to review the issue in detail. With funding from the National Institute of Neurological Disorders and Stroke, Richard launched the Study of Antidepressants in Parkinson’s Disease or SAD-PD.
The effort included 115 people with Parkinson’s disease at 20 sites in the United States, Canada, and Puerto Rico. All the participants had Parkinson’s disease and met the criteria for depression.
About one-third of the participants received paroxetine (brand name Paxil), a selective serotonin reuptake inhibitors (SSRIs); one-third received venlafaxine extended release (brand name Effexor), a serotonin and norepinephrine reuptake inhibitor (SNRI); and one-third received a placebo.
On average, the people receiving paroxetine had a 59 percent improvement and those receiving venlafaxine had a 52 percent improvement in their scores, according to the Hamilton Rating Scale for Depression.
People who received the placebo had a 32 percent improvement. Three other depression rating scales showed similar results. The drugs were generally well tolerated and did not lead to any worsening in motor functioning.
The findings culminate a decade-long research effort by Richard. Today, people are becoming more knowledgeable that depression is oftentimes part of the disease, said Richard, who has witnessed striking improvement in many patients after effective treatment.
“After treatment for depression, patients and their families often see a dramatic difference in how they’re feeling, within a few weeks or months. They have more interest in things. They have more energy; they’re sleeping better. And oftentimes there is a great sense of relief, and a huge burden has been lifted,” said Richard.
She added that sometimes it can be difficult to spot depression in patients, because some symptoms overlap with other symptoms of Parkinson’s. For instance, Parkinson’s patients will be less animated, their voice will be less expressive, and many will have sleep difficulties — but they may not be depressed. Therefore, careful diagnosis is crucial.
The study is published online in Neurology.
Nauert PhD, R. (2015). Newer Antidepressants Effective, Well-Tolerated for Parkinson’s Patients. Psych Central. Retrieved on October 1, 2016, from http://psychcentral.com/news/2012/04/12/newer-antidepressants-effective-well-tolerated-for-parkinsons-patients/37271.html